机构名称：
¥ 2.0
The primary safety assessment of SUNLENCA was based on data from heavily treatment-experienced adult subjects with HIV who received SUNLENCA in a Phase 2/3 trial (CAPELLA; N=72) through Week 52 (median duration on study of 71 weeks) [see Clinical Studies (14)] , as well as supportive data in treatment-naïve adult subjects with HIV who received SUNLENCA in a Phase 2 trial (CALIBRATE; n = 157）到第54周（暴露的中位持续时间为66周）。在Capella中至少有3％的受试者中报告的最常见的不良反应（所有等级）是恶心和注射部位反应。无论严重程度如何，由于不良事件而停止使用Sunlenca治疗的Capella的受试者的比例为1％（1级注射部位结节1受试者）。表3显示了Sunlenca组大于或等于3％的不良反应的频率。
Gilead Sciences 1
主要关键词
相关文件推荐
